A detailed history of Man Group PLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Man Group PLC holds 100,188 shares of CRNX stock, worth $5.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
100,188
Previous 125,714 20.3%
Holding current value
$5.37 Million
Previous $5.63 Million 9.11%
% of portfolio
0.01%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$43.83 - $54.98 $1.12 Million - $1.4 Million
-25,526 Reduced 20.3%
100,188 $5.12 Million
Q2 2024

Aug 14, 2024

BUY
$42.12 - $51.91 $5.3 Million - $6.53 Million
125,714 New
125,714 $5.63 Million
Q3 2023

Nov 14, 2023

BUY
$15.97 - $30.59 $485,599 - $930,150
30,407 New
30,407 $904,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.88B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.